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Abstract Bispecific miniantibodies were constructed by geneti-
cally fusing the CH1 domain of an IgG1 to the C-terminus of a
single-chain Fv fragment (scFv-425), specific for the EGF
receptor, and fusing the CL domain of a kappa light chain to
the C-terminus of a scFv specific for CD2 (scFv-M1). An
efficient dicistronic gene arrangement for functional expression
in Escherichia coli was constructed. Immunoblots demonstrated
correct domain assembly and the formation of the natural CH1-
CL disulfide bridge. Gel filtration confirmed the correct size,
sandwich ELISAs demonstrated bispecific functionality, and
SPR biosensor measurements determined binding to EGF-R in
comparison to bivalent constructs. Bispecific anti-EGF-R/anti-
CD2 miniantibodies are candidates for the immunotherapy of
cancer.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
We present here a novel approach to generate bispeci¢c
miniantibodies which functionally assemble in Escherichia
coli. They are based on single-chain Fv fragments (scFv), in
which the variable domain of the heavy chain (VH) is con-
nected by a glycine-rich linker to the variable domain of the
light chain (VL) [1^3]. Two di¡erent scFv fragments are
brought together by fusing them, via a hinge region, to the
¢rst constant domain of the heavy chain (CH1) or the constant
domain of the U light chain (CL) domain of an antibody. The
CL and CH1 domains form a covalently linked heterodimer
carrying two di¡erent scFv speci¢cities, named CHCL minian-
tibody. This work extends earlier work on multivalent, but
homospeci¢c miniantibodies [4^6], in which small oligomeri-
zation motifs such as amphipathic helices have been used to
create molecules with high avidity.
Bispeci¢c antibodies have been considered as potential
drugs for tumor therapy, mainly for the induction of an anti-
body dependent cell mediated cytotoxicity (ADCC). First clin-
ical trials using bispeci¢c whole antibodies or chemically
crosslinked Fab fragments [7^9] looked promising [10^13].
The strategy of bispeci¢c miniantibodies might, however,
also be useful for a wide range of related applications, such
as the delivery of toxic proteins [14] and small molecule drugs
such as radioisotopes [15,16].
We have chosen to create, as a model system, bispeci¢c
miniantibodies capable of binding to the EGF receptor
(EGF-R) and CD2 at the same time. EGF-R is overexpressed
by a wide range of tumors, whereas CD2 is expressed on
cytotoxic T-cells (CTL) and natural killer cells (NK). Activa-
tion of CTL and NK close to tumor cells has previously been
demonstrated by chemically crosslinked Fab fragments of the
same antibodies from which our scFv are derived [17,18].
Activation of CTL and NK by the CD2 route is potentially
very useful as it requires a second anti-CD2 monoclonal anti-
body [17,18] and thus avoids premature activation of the T-
cells, which would give rise to high toxicity of the bispeci¢c
antibody. The parent monoclonal antibody for the anti-EGF-
R scFv, 425, has already been tested in a clinical study in
patients with advanced laryngeal and hypopharyngeal carci-
nomas [19].
Here we demonstrate that IgG CH1 and U-chain CL do-
mains, fused to two scFv moieties, can be utilized to form
heterodimers, when functionally expressed in E. coli. The ad-
vantage of this format is a longer reach to far apart antigens,
compared to smaller bispeci¢c variants, which is expected to
be advantageous for bridging tumor cells with e¡ector cells. In
addition, the molecular size of six Ig domains has previously
been shown to result in useful half-lives and good tumor-to-
blood ratios [20]. Furthermore, the immunogenicity is ex-
pected to be low, since human sequences can be used for all
components.
2. Materials and methods
2.1. Plasmid construction
An XbaI-HindIII cassette for dicistronic expression of two proteins
was constructed by gene synthesis based on recursive PCR [21]. This
cassette was cloned into a EcoRI- and EcoRV-free derivative of
pASK30 [22] to give pKM30hetrop. In several PCR steps with inter-
mediate subcloning into pCR-ScriptSK (Stratagene, USA) the anti-
EGF-R scFv (named 425) [23], the anti-CD2 scFv (named M1) [18]
(W. Strittmatter, unpublished), the IgG1 CH1 domain including the
¢rst hinge cysteine [24,25], and the U-chain CL domain [26,27] were
cloned into this vector to give pKM30425M1ChCl. The CH1 gene was
ampli¢ed using the forward primer cg1_xho_hinge: TATCCTCGAG
CCGAAGCCGT CTACTCCACC CGGGACTAGT GCAAAGAC-
CA CTCCTCCG and the back primer cg1_nhe: TCTAGCTAGC
ACCACCGCAG TCGCGCGGTA CG. The CL gene was ampli¢ed
using the primers cl_sac: TGACGAGCTC CGCTGATGCT
GCACCGAC and cl_his_hind: TCCCAAGCTT ACTAGTGATG
GTGATGGTGA CCACCACACT CATTCCTGTT GAAG. In addi-
tion, a variant of the scFv M1 with a longer linker, named M1L, was
constructed and cloned to give pKM30425M1LChCl. For compari-
son, the homodimeric miniantibody 425dhlx [4,23] with a hexa-histi-
dine tail was also constructed to give the plasmid pKM30425dhlxh6.
The scFv 425 in the bispeci¢c construct and all homodimeric con-
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structs carry a short N-terminal FLAG tag [28]. All constructs ob-
tained with PCR steps were con¢rmed by sequencing. The correct size
of the proteins M1dhlx, M1Ldhlx, and 425dhlx was veri¢ed by elec-
trospray ionization mass spectrometry.
2.2. Protein expression
Plasmids were transformed either into E. coli JM83 (F3 ara v(lac-
proAB) rpsL (strr) [x80dlac v(lacZ)M15] thi) or BF18-61 (R. Wender-
oth, unpublished), a RV308 (lac74-galISII: :OP308-strA) derivative.
Protein expression was carried out in LB broth in shake £asks, con-
taining 0.1 g/l ampicillin. Overnight cultures were grown at 26‡C and
the main culture was inoculated to an OD550 of 0.15 (typical dilution
of 1:25^1:30) and grown at 25‡C. Cells were induced at an OD of
0.5^0.6 and harvested by centrifugation at 5000Ug after reaching a
plateau phase, typically after 3^4 h at an OD of 2^2.5. Cell pellets
were immediately frozen at 380‡C and stored until use.
2.3. Protein puri¢cation
Cell pellets with miniantibody 425CH-M1CL were thawed in a sev-
en-fold volume of PBS (50 mM Na-phosphate, 150 mM NaCl) bu¡er,
containing 10 mM imidazole and 1 mM MgCl2, pH 7.4, and sonicated
three times with continuous temperature monitoring in an ice-ethanol
bath, between 3 and 8‡C. To the lysates Tween-20 was added to a
¢nal concentration of 0.005% (v/v), and the sample was clari¢ed by
centrifugation at 49 000Ug for 30 min, and ¢ltered through 0.2 Wm
pores. The sample was applied to a Ni2-NTA column (Qiagen, Ger-
many) with PBS-Tween as running bu¡er at 4‡C, washed with 10 mM
and 25 mM imidazole and eluted with 250 mM imidazole. The elution
fraction was directly applied to an anti-425 idiotypic immunoa⁄nity
column. After washing with PBS-Tween to baseline, samples were
eluted with acidic bu¡er (100 mM glycine, 500 mM NaCl, and
0.005% Tween adjusted to pH 2.8 with HCl) into vials containing a
predetermined amount of 1 M Tris base to adjust the eluate immedi-
ately back to pH 7.5. After puri¢cation samples were dialyzed against
PBS-Tween. Miniantibody 425-CH/M1-CL expressed in BF-18 was
typically obtained at 125 Wg/(lWOD550) and miniantibody 425-CH/
M1L-CL expressed in JM83 at 20 Wg/(lWOD550).
2.4. SDS-PAGE, Western blot
Samples were analyzed by SDS-PAGE (12% minigels with 5%
stacking gels) in sample bu¡er either with or without 100 mM
DTT. Protein bands were quantitated from reducing samples by den-
sitometry (Densitometer 300A and Imagequant software, Molecular
Dynamics, USA). Immunoblots on nitrocellulose membranes were
stained with Ponceau-S and protein bands marked. After blocking
with 3% skim milk powder, proteins were detected, ¢rst using an
anti-FLAG (Kodak, USA) or anti-His tag [29] monoclonal antibody,
respectively, and second an anti-mouse Fc-peroxidase conjugate (Sig-
ma, USA). The blot was developed with precipitating BM-blue
(Boehringer Mannheim, Germany).
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Fig. 1. Model of the protein structure (A), scheme of the gene arrangement (B), and detail of plasmid pKM30425M1ChCl (C) of the bispeci¢c
miniantibody. The model structure was assembled from minimized structures of a variable domain (PDB ¢le 4FAB) with an attached linker,
an extended modeled hinge region, and the constant domains CH1 and CL (PDB ¢le 1IKF). The gene sequence shows the C-terminal part of
the ¢rst protein 425CH1 including the Shine-Dalgarno (SD-2) sequence and the start of the second protein M1CL including the modi¢ed pelB
signal sequence.
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2.5. Sandwich ELISA
ELISA 96-well plates (Nunc Maxisorb, USA) were coated with 50
Wl per well of 300 ng/ml CD2 extracellular domains (kindly provided
by Drs. K. Willis, S. Simon, and A. van der Merwe) in PBS pH 7.4.
After blocking with 3% skim milk powder, ¢rst the bispeci¢c minianti-
body sample was added, second, the anti-425 idiotypic monoclonal
antibody, and third, the polyclonal anti-mouse Fc-peroxidase conju-
gate. The ELISA was developed with soluble BM-blue (Boehringer
Mannheim).
2.6. Size exclusion chromatography
Samples of 30 Wl were loaded onto a Superose-12 PC 3.2/30 column
(Pharmacia, Sweden) equilibrated in PBS containing 0.005% Tween.
Molecular weights were determined according to a linear regression of
molecular weight standards (Sigma, USA) analyzed under the same
conditions.
2.7. Surface plasmon resonance biosensor
Surface plasmon resonance biosensor measurements were per-
formed with the BIAcore instrument (Biacore, Sweden). EGF-R (70
Wl) at an approximate concentration of 0.2 Wg/ml in 10 mM Na-ace-
tate, pH 4.5 was coupled to a CM5 sensor chip (Biacore, Sweden)
using standard EDC (1-ethyl-3-(3-dimethyl-aminopropyl)carbodi-
imide-HCl) NHS (N-hydroxysuccinimide) coupling chemistry with
subsequent blocking by ethanolamine. The EGF receptor extracellular
domain was puri¢ed by a⁄nity chromatography from A431 cell cul-
ture supernatant (W. Strittmatter, unpublished data).
3. Results
3.1. Construction of a cloning cassette for e⁄cient polycistronic
expression
The translation e⁄ciency of downstream proteins in poly-
cistronic expression can be a problem if the spacing between
the ¢rst and second coding sequence is too large [30]. There-
fore, a cassette for dicistronic expression was designed with
minimal spacing between the stop codon of the ¢rst and the
start codon of the second gene. This was achieved by placing
the Shine-Dalgarno sequence for the second protein within the
coding sequence of the ¢rst protein as depicted in Fig. 1C.
The Shine-Dalgarno sequence itself and the distance to the
start codon were designed according to current knowledge
[31^33]. To avoid read-through two stop codons were intro-
duced, which do not interfere with the requirements for the
nucleotides between the Shine-Dalgarno sequence and the
protein translation start. The second translation product is
also in a di¡erent frame, which should further promote reor-
ientation of the ribosome. To avoid recombination between
two similar pelB sequences and to facilitate cloning with
unique restriction enzymes, the second pelB sequence was
modi¢ed. A silent FseI site was introduced, which cuts rarely
in antibodies, as well as a mutation for a NotI site [34].
3.2. Expression and assembly determined by SDS-PAGE,
Western blot, and gel ¢ltration
As seen in the IMAC elution in Fig. 2A, scFv-M1CL, en-
coded as a downstream gene in the dicistronic arrangement,
was expressed at least to the same extent as the upstream
scFv-425CH. In contrast, when both proteins were expressed
separately in the same homodimeric miniantibody format,
scFv-M1 expressed signi¢cantly less functional protein than
scFv-425 (data not shown). This is a strong indication that
the designed polycistronic expression works well. After the
anti-idiotypic a⁄nity puri¢cation, speci¢c for the scFv-425,
425CH is present in slight excess. Quanti¢cation of the inten-
sity of the bands on the Coomassie stained gel indicates that
about 63% heterodimer of the puri¢ed 425-CH is combined
with the M1-CL after anti-idiotypic chromatography. As de-
duced from absorbance spectra, a typical 2 l shake £ask cul-
ture using strain BF-18 yields in total about 800 Wg protein
after anti-scFv-425 immunoa⁄nity puri¢cation and dialysis,
corresponding to approximately 500 Wg bispeci¢c minianti-
body. The usage of strain JM83 results in slightly less protein.
In the case of the miniantibody with a longer linker between
VH and VL of M1, named scFv-M1L, the two scFv fusion
proteins are di⁄cult to distinguish on SDS-PAGE. The usage
of the longer linker gave in general less pure protein.
The identity of protein bands after anti-idiotypic a⁄nity
chromatography was determined by immunoblot detection
as seen in Fig. 2B,C. The 425-CH fusion contains a FLAG
epitope and the M1-CL fusion a His tag, which can both be
speci¢cally detected. The anti-His tag monoclonal antibody
solely recognizes C-terminal His tags, and therefore the 425-
CH His tag, which is followed by two additional amino acids,
is not detected. In a reducing SDS-PAGE, both bands are
resolved, whereas in an oxidizing gel both antibodies detect
the same band at a molecular weight corresponding to a het-
erodimer, indicating that it contains both species. A slight
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Fig. 2. Identi¢cation of CHCL miniantibody protein bands. A: Coomassie stained SDS gel of the puri¢cation of the bispeci¢c miniantibody
425CHM1CL after IMAC (1) and after anti-idiotypic a⁄nity chromatography (2). B, C: Western blot of the 425CHM1CL miniantibody. Two
blots with the same sample were stained with either anti-FLAG (B) or anti-His tag monoclonal antibody (C). In both cases the bispeci¢c mini-
antibody was loaded under reducing conditions (red) and under oxidizing conditions (ox). Under reducing conditions the two proteins forming
the miniantibody dissociate and are stained separately: the anti-FLAG Ab detects 425-CH and the anti-His tag Ab detects M1-CL. Under oxi-
dizing conditions both antibodies detect the same band at the molecular weight of the heterodimer. Protein bands were marked in a Ponceau-S
stain prior to immunostaining.
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degradation band can also be seen. The 425-CH chain com-
prises 372 residues with a molecular weight of 39 636 Da (cal-
culated without disul¢de bridges), and the M1-CL 364 residues
with 39 819 Da.
Size exclusion chromatography revealed a molecular mass
of 87 kDa for the CHCL miniantibody, in good agreement
with the calculated mass of 79.5 kDa. For comparison, the
homodimeric miniantibody 425dhlx was measured with a mo-
lecular weight of 77 kDa and for the M1dhlx with a molecular
weight of 75 kDa, both also in good agreement with the
calculated masses of 67 kDa and 66 kDa, respectively.
3.3. Bispeci¢city detected in ELISA
Bispeci¢c binding was analyzed in a sandwich ELISA. After
coating with CD2, the ELISA plate was incubated ¢rst with
the bispeci¢c miniantibody, second with a monoclonal anti-
idiotypic antibody recognizing the EGF receptor speci¢city,
and third for detection with a peroxidase-conjugated polyclo-
nal mouse Fc-speci¢c serum. The signal at 200 nM minianti-
body could be inhibited by co-incubation with either 1 WM
CD2 or 1 WM EGF-R, indicating that binding is speci¢c on
both sides Fig. 3.
3.4. EGF receptor binding measured with surface plasmon
resonance
The functionality of the anti-EGF receptor scFv was fur-
ther tested using the BIAcore instrument. The experiment was
designed to detect possible loss in avidity when switching from
the natural bivalent binding of a monoclonal antibody to the
monovalent binding in the bispeci¢c miniantibody format.
Therefore, EGF-R was coupled to the sensor chip at a high
coating density of 1600 resonance units (RU). Indeed, the
homodimeric miniantibody scFv-425dhlx (Fig. 4B) fully re-
produces the binding characteristics of the monoclonal anti-
body (Fig. 4C), whereas the CHCL miniantibody, which binds
EGF-R only monovalently, displays a faster o¡-rate (Fig.
4A). Avidity is di⁄cult to express in exact biophysical terms,
since it depends on molecular size and ligand density [5,6].
However, using the same surface and molecular concentra-
tions of analyte, direct comparisons can be made. The di¡er-
ences seen in the signal intensity re£ect the di¡erences in the
molecular size (425-CH/M1-CL 79 kDa, 425dhlx 67 kDa, mAb
150 kDa), and the higher o¡-rate in the case of the bispeci¢c
miniantibody.
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Fig. 4. BIAcore sensorgrams of EGF-R binding. A dilution series of
miniantibody 425CH-M1CL (A), homobivalent miniantibody 425-
dhlx (B) and the parental monoclonal antibody (C). Binding to a
surface coated with 1600 RU EGF-R was measured at concentra-
tions of 25, 50, 100, 200, 400, 800, and 1600 nM for each molecule.
Fig. 3. Sandwich ELISA for the analysis of bispeci¢city. CD2 was
coated, and the ELISA plate was incubated with bispeci¢c minianti-
body 425CH(anti-EGF-R)-M1CL(anti-CD2). Anti-EGF-R speci¢city
was detected with an anti-idiotypic monoclonal antibody directed
against the 425 scFv. Inhibition with 1 WM CD2 and 1 WM EGF-R
demonstrates speci¢city. The secondary antibody was a peroxidase
conjugated anti-Fc speci¢c polyclonal serum. The blank value with-
out bispeci¢c miniantibody was subtracted from all measurements.
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4. Discussion
The results presented demonstrate that functionally bispe-
ci¢c miniantibodies, heterodimerized via CH1 and CL, can be
obtained in functional form from E. coli. It was shown that
such complex molecules comprising heterodimers of three dif-
ferent Ig domains, each with disul¢de linkages between them,
can be functionally formed in E. coli. A new polycistronic
expression cassette was successfully employed for this pur-
pose.
Several other techniques have been developed to combine
two di¡erent antibody binding sites in one molecule [6]. Con-
ceptually, the simplest form of bringing two speci¢cities to-
gether is a polypeptide linker between two scFv [35,36] or Fab
fragments [37]. Another minimal size antibody derivative is
the diabody [38], with two crosswise paired scFv, which are,
however, very restricted in reach. Simple heterodimerization
domains fused to scFv like the Jun/Fos coiled-coil lead to a
mixture of homo- and heterodimers [39] and need to be as-
sembled by refolding [40]. Reengineering of the CH3 domain
into a heterodimerization domain [41] was shown to be capa-
ble of forming antibody immunoadhesin hybrids and may also
be useful for heteromerization. A large molecule is the result
of the fusion of scFv fragments to whole antibodies serving as
dimerization devices [42]. The CHCL miniantibody strategy
described here leads to the desired assembly with a small
size but a long reach.
The anti-EGF-R scFv-425 and the anti-CD2 scFv-M1 were
constructed from monoclonal antibodies without further mu-
tations. The scFv-425dhlx, homodimerized via a helix-turn-
helix module, expresses well [23], whereas the homodimeric
M1dhlx causes expression problems. Taking this into account,
the robustness and yield of about 125 Wg/(lWOD) of a simple
CHCL miniantibody shake £ask culture is encouraging and
invites scFv optimization. The reasons for the lower ¢nal
yields with the scFv-M1L with a longer linker, which are
also seen in the homodimeric construct (data not shown),
are most likely due to an increased toxic e¡ect which limits
the cell growth. This is even more pronounced in strain JM83.
The fact that the designed dicistronic expression cassette
presented here appears to be overachieving in terms of the
functional yield of the downstream protein can most likely
be attributed to di¡erences in folding and membrane trans-
location e⁄ciency of the CH1 and CL domains. However, the
simultaneous coding of both proteins on one plasmid o¡ers
the possibility of reproducible ¢ne tuning.
The scFv-M1, regardless of whether it is expressed as a
heterodimeric or homodimeric miniantibody, does not reach
the slow o¡-rate of its parental monoclonal antibody (data
not shown). This accounts for the low signals seen in sand-
wich ELISA, since in this assay two additional incubation
steps were used. In contrast, the homodimeric scFv-425 has
the same binding characteristics as the monoclonal antibody
as seen in BIAcore. The bispeci¢c miniantibody is only mono-
valent for each speci¢city. Based on previous experiments with
Fab fragments chemically coupled to form heterodimers [18],
which showed antibody-dependent cell killing, monomeric
binding in the presented case appears to be su⁄cient for the
application of the miniantibody.
The implementation of two optimization strategies is likely
to increase yields dramatically. First, the engineering of the
scFv molecule for improving their folding characteristics [43^
45] will ensure that scFv from well analyzed monoclonal anti-
bodies or natural libraries can be further improved to meet
the protein sequence criteria for high level expression in E.
coli. Second, the knobs into holes engineering approach [41] is
an attractive perspective to further optimize the heteromeriza-
tion of CH1-CL as well as the speci¢c formation of the scFv
itself. In conclusion, the use of CH1 and CL as heterodimeri-
zation tool appears to be a promising strategy for generating
heterodimeric proteins.
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